The Drug Enforcement Administration (DEA) is being put on notice—again—over prolonged delays in processing a petition to reschedule psilocybin from a doctor who wants to use it to treat terminally ill patients, with an updated reminder that President Donald Trump has now made clear his administration’s intent to streamline psychedelic medicine access.
In a letter sent to an appellate staffer with the Justice Department’s civil division on Wednesday, an attorney representing Sunil Aggarwal of the AIMS Institute laid out the years-long timeline since a petition was first filed with DEA in 2022 requesting that psilocybin be moved from Schedule I to Schedule II of the Controlled Substances Act (CSA).
Aggarwal and AIMS have been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal right-to-try (RTT) laws.
However, after a dizzying back-and-forth that involved an initial DEA denial of the rescheduling petition, appeals, court hearings and DOJ’s forwarding of the rescheduling petition to the Department of Health and Human Services (HHS) in August 2025, the agency went silent.
“We have had no information about the status of the petition since that time,
Read full article on Marijuana Moment
